Dexamethasone intravitreal implant in the treatment of diabetic macular edema
10.3980/j.issn.1672-5123.2022.12.11
- VernacularTitle:地塞米松玻璃体内植入剂治疗糖尿病性黄斑水肿的研究进展
- Author:
Ke-Ke HU
1
;
Yan-Nian HUI
1
;
Hong-Jun DU
1
Author Information
1. Department of Ophthalmology, Eye Institute of PLA, Xijing Hospital, Air Force Medical University, Xi'an 710032, Shaanxi Province, China
- Publication Type:Journal Article
- Keywords:
Dexamethasone intravitreal implant;
diabetic macular edema;
inflammatory;
efficacy;
safety
- From:
International Eye Science
2022;22(12):1992-1996
- CountryChina
- Language:Chinese
-
Abstract:
Diabetic macular edema(DME)is the main cause of vision loss in patients with diabetes. Hyperglycemia leads to disruption of the blood-retinal barrier by triggering a pro-inflammatory and pro-angiogenic cascade, leading to intraretinal or subretinal fluid accumulation in the macula. Intravitreal administration of steroids represents an alternative for DME, while injection-related complications include endophthalmitis, vitreous hemorrhage, and retinal detachment. In order to reduce the risks and complications, dexamethasone intravitreal implant(DEX implant; Ozurdex®)were developed. DEX implant is a novel, artificially degradable sustained-release implant, with the advantages of reasonable release profile, strong anti-inflammatory, rapid improvement of macular edema, good bioavailability and safety. DEX implant provides a new choice for the treatment of patients with DME and has been recommended by several guidelines. This article reviews the latest research progress of DEX implant in the clinical treatment of DME.
